Skip to content

Nasal High Flow Therapy for Respiratory Support in the Emergency Department, a Point Prevalence Study

Nasal High Flow Therapy for Respiratory Support and the need for escalation of care in the Emergency Department, a Point Prevalence Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12621001167853
Enrollment
76
Registered
2021-08-27
Start date
2023-04-17
Completion date
2023-05-15
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The participant population is Adult Emergency Department (ED) patients who have a requirement for respiratory support. The purpose of this study is to examine the nature of the respiratory support delivered in the ED. There shall be a specific focus on Nasal High Flow (NHF) therapy delivered to adults in the ED. This study shall explore the influence that this support has upon patient outcomes. The overarching research questions are: • What is the nature of the NHF delivered to adults in the ED setting? • What influence does the delivery of NHF have upon adult ED patient outcomes? The five specific research sub-questions are: • Who receives NHF in the ED? • How is NHF delivered in the ED? • Which patients receiving NHF require escalation of therapy in the ED? • What are the effects seen with NHF therapy on physiological and patient-centred outcomes?

Interventions

Nasal High Flow therapy delivered via a nasal interface : Heated and humidified gas flow rates from 5- 60 L/min FiO2 21- 100% Temperature 32-37 C Patients will receive this therapy regardless of whether they are enrolled in the study or not, and at the discretion of their clinicians Only data from clinical records shall be collected ie there is no additional involvement for patients The duration of patient involvement is 30 days post ED admission The data will be collected in 2 , 12 hour cross

Nasal High Flow therapy delivered via a nasal interface : Heated and humidified gas flow rates from 5- 60 L/min FiO2 21- 100% Temperature 32-37 C Patients will receive this therapy regardless of whether they are enrolled in the study or not, and at the discretion of their clinicians Only data from clinical records shall be collected ie there is no additional involvement for patients The duration of patient involvement is 30 days post ED admission The data will be collected in 2 , 12 hour cross sections of time separated by 4 weeks The data sources are from within 4 EDs within 4 District Area Health Boards (DHBs) in NZ

Sponsors

Health Research Council NZ
Lead SponsorUniversity

Eligibility

Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Adult Emergency Department Patient Requirement for any form or combination of respiratory support (via COT, NIV, NHF, BiPaP, CPAP , nebuliser , and or IPPV)

Exclusion criteria

No requirement for respiratory support

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026